Analyst Price Targets — AKTS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 15, 2026 8:07 pm | Christopher Raymond | Raymond James | $40.00 | $20.69 | TheFly | Aktis Oncology initiated with a Strong Buy at Raymond James |
| June 2, 2026 3:44 pm | Robert Burns | H.C. Wainwright | $35.00 | $19.61 | TheFly | Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright |
| March 9, 2026 10:15 am | — | H.C. Wainwright | $30.00 | $19.06 | TheFly | Aktis Oncology initiated with a Buy at H.C. Wainwright |
| February 3, 2026 11:26 am | — | Leerink Partners | $31.00 | $21.98 | TheFly | Aktis Oncology initiated with an Outperform at Leerink |
Latest News for AKTS
Aktis Oncology trades at a $1.1B market cap with $540M cash, pricing its pipeline and Eli Lilly collaboration at $560M. The investment thesis hinges on the mini-protein platform targeting Nectin-4, with lead asset AKY-1189's Phase Ib data expected Q1 2027 as a binary catalyst. My conservative base case yields $12/share equity value, well below the ~$20 market price, implying patient expansion is already priced in.
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the…
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported first-in-human clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate…
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.
BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported financial results and business highlights for the first quarter ended March 31, 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AKTS.
U.S. House Trading
No House trades found for AKTS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.